Relmada Therapeutics to Present at Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

Rhea-AI Summary

Relmada Therapeutics (NASDAQ: RLMD) announced that CEO Sergio Traversa will present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on September 21, 2021, at 12:25 PM ET. Attendees can access a live webcast of the event here or through the Relmada website. The company is advancing REL-1017, a novel NMDA receptor channel blocker, in late-stage development for major depressive disorder (MDD), demonstrating promising results in Phase 2 trials. An archived replay will be available for 90 days post-event.

CORAL GABLES, Fla., Sept. 17, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer of Relmada, will present at the annual Oppenheimer Fall Healthcare Life Sciences and MedTech Summit, on September 21, 2021, at 12:25 pm ET.

Participants may access a live webcast of the event through the following link: https://wsw.com/webcast/oppenheimer16/rlmd/2780365

The webcast can also be accessed in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar. An archived replay of the event will be available for 90 days after the conclusion of the presentation.

About REL-1017

REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the treatment of MDD. The ongoing RELIANCE Clinical Research Program is designed to evaluate the potential for REL-1017 as the first rapid-acting, oral, once-daily antidepressant treatment. In a Phase 2 trial, REL-1017 demonstrated rapid, robust and sustained antidepressant effects with statistically significant improvements compared to placebo in all tested measures of depression. The Phase 2 study also confirmed the very favorable safety, tolerability and pharmacokinetics profile of REL-1017 observed in previously completed Phase 1 studies.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults.  In addition, the Company is advancing a clinical-stage program in neurodegenerative diseases based on psilocybin and derivates molecules. Learn more at www.relmada.com.

Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the expected use of the proceeds from the offering. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.

Investor Contact: 
Tim McCarthy 
LifeSci Advisors 
212-915-2564 
tim@lifesciadvisors.com

Media Inquiries: 
FischTank PR  
relmada@fischtankpr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/relmada-therapeutics-to-present-at-oppenheimer-fall-healthcare-life-sciences-and-medtech-summit-301379487.html

SOURCE Relmada Therapeutics, Inc.

FAQ

What is the significance of Relmada's CEO presenting at the Oppenheimer Summit?

The presentation highlights Relmada Therapeutics' focus on major depressive disorder and progress with REL-1017, emphasizing its commitment to mental health innovations.

When is Relmada's presentation at the Oppenheimer Summit scheduled?

Relmada Therapeutics' presentation is scheduled for September 21, 2021, at 12:25 PM ET.

How can I access the webcast of Relmada's presentation?

The webcast can be accessed live at this link or via the Investors section on Relmada's website.

What are the key findings from the Phase 2 trial of REL-1017?

The Phase 2 trial of REL-1017 showed rapid, robust, and sustained antidepressant effects with significant improvements over placebo, along with a favorable safety profile.

What is the potential of REL-1017 in treating major depressive disorder?

REL-1017 aims to be the first rapid-acting, oral, once-daily antidepressant, currently in late-stage development under the RELIANCE Clinical Research Program.